Business
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1’26 with Cash, Cash Equivalents
About this update from Collegium Pharmaceutical, Inc.
[{"type":"image","alt":"Collegium Pharmaceutical, Inc.","displaySize":"","headline":null,"caption":"Collegium Pharmaceutical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/d00262a0b75d92cc28a42bcc16d20a1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S5ES9Zc2Z2psQENPovttBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/d00262a0b75d92cc28a42bcc16d20a1a","width":300,"height":100},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/S5ES9Zc2Z2psQENPovttBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/d00262a0b75d92cc28a42bcc16d20a1a","width":300,"height":100}},"lazy":false},{"type":"text","content":"– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – ","length":76,"tagName":"p"},{"type":"text","content":"– Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year –","length":91,"tagName":"p"},{"type":"text","content":"– On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio –","length":202,"tagName":"p"},{"type":"text","content":"– Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year –","length":96,"tagName":"p"},{"type":"text","content":"– Ended Q1’26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million –","length":102,"tagName":"p"},{"type":"text","content":"– Reaffirmed Full-Year 2026 Guidance for the Current Business –","length":63,"tagName":"p"},{"type":"text","content":"– Conference Call Scheduled for Today at 8:00 a.m. ET –","length":55,"tagName":"p"},{"type":"text","content":"STOUGHTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter ended March 31, 2026, and provided a business update.","length":203,"tagName":"p"},{"type":"text","content":"“In the first quarter, we made meaningful progress on our 2026 strategic priorities, including delivering strong performance for JORNAY PM and continued durability from our pain portfolio” said Vikram Karnani, President and Chief Executive Officer. “We genera...